A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)

ABSTRACTDTaP5-HBV-IPV-Hib (Vaxelis®) is a hexavalent combination vaccine (HV) indicated in infants and toddlers for the prevention of diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive disease due to Haemophilus influenzae type b. Switching between HVs during the childhood vacc...

Disgrifiad llawn

Wedi'i Gadw mewn:

Manylion Llyfryddiaeth
Prif Awduron:	Andrea Guerra (Awdur), Claudio Costantino (Awdur), Federico Martinon-Torres (Awdur), Soeren Westerholt (Awdur), Courtney Lambeth (Awdur), Ziqiang Chen (Awdur), Jessie Lumley (Awdur), Tomas Marcek (Awdur), David Johnson (Awdur), Marissa Wilck (Awdur)
Fformat:	Llyfr
Cyhoeddwyd:	Taylor & Francis Group, 2024-12-01T00:00:00Z.
Pynciau:	article
Mynediad Ar-lein:	Connect to this object online.
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Rhyngrwyd

Connect to this object online.

3rd Floor Main Library

Manylion daliadau o 3rd Floor Main Library
Rhif Galw:	A1234.567
Copi 1	Ar gael

A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)

Rhyngrwyd

3rd Floor Main Library

Eitemau Tebyg